A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: The role of a novel G796A mutation in exon 20 of EGFR

Hidetaka Uramoto, Takeshi Uchiumi, Hiroto Izumi, Kimitoshi Kohno, Tsunehiro Oyama, Kenji Sugio, Kosei Yasumoto

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

Subsets of non-small cell lung cancer (NSCLC) patients who carry activating somatic mutations of the epidermal growth factor receptor (EGFR) have demonstrated an increased probability of obtaining objective responses to the receptor tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. However, a substantial proportion of the cases with somatic mutations, which suggest sensitivity to gefitinib, are primary resistant to it. A primary resistant case of lung adenocarcinoma that was found to carry both delE746-A750 and a G796A mutation in the EGFR is reported. In vitro, a stable clone of cells bearing the G796A mutation was approximately 50,000-fold less sensitive to gefitinib in comparison to cells carrying the delE746-A750 mutant EGFR. This study suggests that screening tumour samples for a range of EGFR mutations may improve our ability to identify the patients most likely to benefit from EFGR TKIs.

Original languageEnglish
Pages (from-to)2297-2303
Number of pages7
JournalAnticancer research
Volume27
Issue number4 B
Publication statusPublished - Jul 1 2007
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: The role of a novel G796A mutation in exon 20 of EGFR'. Together they form a unique fingerprint.

Cite this